|
|
Managing Director - Menlo Park, California
|
 |
Patrick Enright is a founder and Managing Director
of Longitude Capital. He focuses on investments in biotechnology.
From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life
sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund,
where he invested in privately-held and publicly-traded biotechnology companies. Mr. Enright began his investment
career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies.
Mr. Enright also has significant life sciences operations experience including senior executive positions at Valentis,
Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche) and Sandoz (now Novartis).
He currently serves on the boards of CardioDx, Corcept Therapeutics (NASDAQ: CORT), InfaCare Pharmaceuticals,
Jazz Pharmaceuticals (NASDAQ: JAZZ) and Xanodyne Pharmaceuticals.
He has previously served on the boards of
Codexis (NASDAQ: CDXS), Horizon Therapeutics (acquired), MAP Pharmaceuticals (NASDAQ: MAPP),
Prestwick Pharmaceuticals (acquired), Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM).
Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S.
in Biological Sciences from Stanford University.
|
|
|
|
